Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tau oligonucleotide
- Development stage
- Preclinical
- Lead developer
- Manifold Bio
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Tau oligonucleotide is a preclinical-stage therapeutic candidate being developed by Manifold Bio for the treatment of Alzheimer's disease and other rare tauopathies. The program utilizes a neuron-targeted approach, employing either antisense oligonucleotides (ASOs) or small interfering RNA (siRNA) to modulate the expression or processing of the tau protein. By specifically targeting neurons, the therapy aims to reduce the accumulation of pathological tau aggregates, which are a hallmark of neurodegeneration. The drug is engineered using Manifold Bio's protein design and delivery platform to optimize its pharmacokinetic profile and therapeutic index within the central nervous system.
- Other names
- Neuron-targeted tau oligonucleotide
02
Targets
MAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on tau oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tau oligonucleotide.